Channels - In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan :: FRELIP Discovery

Similar Items: In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan

Quick Look
Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
Quick Look
Update on the comparative in vitro activity of cefiderocol and four β-lactam–β-lactamase-inhibitor combinations against clinically important Gram-negative pathogens
Quick Look
Contemporary multicentre analysis of carbapenemases distribution among clinical carbapenem-resistant Enterobacterales in Lebanon
Quick Look
Occurrence of β-lactamases among Enterobacterales isolates from 22 US hospitals in a 10-year period: report from the International Network for Optimal Resistance Monitoring (INFORM) programme
Quick Look
Evaluation of three variants of the carbapenem inactivation method for carbapenemase detection in Enterobacterales and description of the cCIM, supplemented with cloxacillin
Quick Look
Genomic epidemiology of carbapenem resistance in Acinetobacter baumannii in Chile
Quick Look
Carbapenem resistance in community-acquired urinary tract infections caused by Klebsiella pneumoniae and Escherichia coli in Morocco: a multicentre study (January 2022–December 2023)‘Carbapenem resistance in community UTIs in Morocco’
Quick Look
Incidence proportion and divergent performance of risk factors for carbapenem-resistant Gram-negative bacteria bloodstream infections across haematological cohorts
Quick Look
Emergence of ST383 carbapenem-resistant Klebsiella pneumoniae harbouring blaNDM-5 and blaOXA-48 carbapenemase genes in a Romanian tertiary-care hospital
Quick Look
Comparative evaluation of the activity of novel β-lactam antibiotics against difficult-to-treat Pseudomonas aeruginosa clinical isolates
Quick Look
Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
Quick Look
In vitro activity of eravacycline and comparator agents against Gram-negative and Gram-positive bacteria: results from China Antimicrobial Surveillance Network between 2017 and 2019
Quick Look
Immune Checkpoint Inhibitor–Associated Myocarditis: A Retrospective Case Series
Quick Look
P74 Addition of probenecid to β-lactam antibiotics in the treatment of skin and soft tissue infections: a systematic review
Quick Look
Colonisation with extended spectrum beta-lactamase producing and carbapenem-resistant enterobacterales in children admitted to a paediatric referral hospital in South Africa
Quick Look
Factor eight inhibitor bypassing activity for refractory bleeding in coronary artery bypass grafting: A propensity‐matched analysis
Quick Look
12 | In vitro study emulating muscle response to stimuli exploiting 3D tissue model
Quick Look
Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin in Clavispora lusitaniae in vitro
Quick Look
Approaches to Collect Comprehensive Electronic Patient Data Across Multiple Providers and Payers for Research: Landscape Analysis
Quick Look
Real-world clinical decision of andexanet alfa administration for intracranial hemorrhage during anticoagulant therapy using factor Xa inhibitor
Quick Look
46 | Investigating the impact of the tumor secretome on in vitro human skeletal and cardiac muscle models of cancer-induced cachexia
Quick Look
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib
Quick Look
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
Quick Look
P46 Development of 3D in-vitro tuberculosis spheroid granuloma model using co-culture PBMCs and BEAS-2B with a nanoscaffold insert